← All drugs Report issue

diethylenetriaminepentaacetate

Small moleculeapprovedOrphan Drug ^FDA

Approved

Aug 11, 2004

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1

0

Phase 2

0

Phase 3

0

Phase 4

0

Timeline

2000s

Apr 28, 2004
Orphan Drug Designation
Aug 11, 2004
Hameln Pharma GmbH — Earliest FDA Approval
Aug 11, 2004
Hameln Pharma GmbH — NDA Secondary Org
Aug 11, 2004
Hameln Pharma GmbH — NDA Organization
Aug 11, 2004
Hameln Pharma GmbH — Marketing Organization

Indications

Approved for

Radioactivity (approved 2004)

Mechanism of action

LeadCHELATING AGENT
Lead chelating agent

Approval history

approvedPriority reviewAug 11, 2004

Chemistry & pharmacology

Loading structure…

SMILES

[Na+].[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O

Mol. weight: 497.354 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Parenteral, Topical
Availability: Discontinued

Oral

No

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

calcium-dtpa
calcium trisodium pentetate
calcium trisodium pentetate
calcium trisodium pentetate
calcium trisodium pentetate
pentetate calcium trisodium
pentetate calcium trisodium
pentetate calcium trisodium
pentetate calcium trisodium
pentetate calcium trisodium
pentetate zinc trisodium
pentetate zinc trisodium
pentetate zinc trisodium
pentetate zinc trisodium
pentetate zinc trisodium
trisodium calcium diethylenetriaminepentaacetate
trisodium zinc diethylenetriaminepentaacetate

Organizations

Marketing (3)

Organization	Org type	Relationship	Date
Hameln Pharma GmbH	For profit	NDA2	Aug 11, 2004
Hameln Pharma GmbH	For profit	NDA	Aug 11, 2004
Hameln Pharma GmbH	For profit	MKTG	Aug 11, 2004